PJSC Pharmsynthez (LIFE.ME)

PJSC Pharmsynthez (LIFE.ME) — VMCI valuation read

LIFE.ME screens at VMCI 38/100, a 12-point gap below the Healthcare sector median (50). For a mid-cap PJSC Pharmsynthez share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

LIFE.ME has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: LIFE.ME trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -2.1x leaves covenant headroom, which sets the rate-cycle exposure for PJSC Pharmsynthez.

LIFE.ME fell 3.9% over the trailing 7 days, with a -13.8% read on a 30-day basis.